FindTrial
Sign In

A study based on CT radiomics for distinguishing benign from malignant renal tumors and assessing their aggressiveness

A study based on CT radiomics for distinguishing benign from malignant renal tumors and assessing their aggressiveness

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108484
Enrollment
Unknown
Registered
2025-09-01
Start date
2025-09-05
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

Gold Standard:Pathological diagnosis
Index test:CT-based radiomics analysis

Sponsors

The Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Pathologically confirmed renal tumors (including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, angiomyolipoma, and oncocytoma). 2.Contrast-enhanced CT scan was performed preoperatively.

Exclusion criteria

Exclusion criteria: 1.Pure cystic clear cell renal cell carcinoma; 2.Poor-quality CT images;

Design outcomes

Primary

MeasureTime frame
Accuracy;Sensitivity;AUC;Specificity;—

Countries

China

Contacts

Public ContactJun Liu

The Second Xiangya Hospital, Central South University

junliu123@csu.edu.cn+86 731 85292116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026